UNLIMITED TURBO LONG - ELI LILLY & CO | Market Closed - Euronext Paris 12:30:03 2024-05-28 pm EDT | ||
| 4.377 EUR | -4.52% |
|
| Current month | +10.70% | ||
| 1 month | +37.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 4.377 | -4.52% |
| 24-05-27 | 4.584 | +2.32% |
| 24-05-24 | 4.48 | -3.49% |
| 24-05-23 | 4.642 | +7.43% |
| 24-05-22 | 4.321 | -1.71% |
Real-time Euronext Paris
Last update May 28, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| PL5NB | |
| ISIN | NLBNPNL2ORU3 |
| Date issued | 2024-03-13 |
| Strike | 582.4 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 2.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.668 € |
|---|---|
| Lowest since issue | 2.89 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Certificates
- PL5NB Certificat
